Abstract: The present invention relates to a pharmaceutical dosage form for application to a mucous membrane, in particular to a buccal, intestinal, rectal or vaginal mucous membrane, comprising at least one sheet like, in particular film shaped, foil shaped or wafer shaped preparation comprising the active pharmaceutical ingredient, a release mechanism, and a trigger mechanism, wherein the trigger mechanism is adapted to trigger, at a predetermined site of action, in particular of the gastrointestinal tract, of the rectum or of the vagina, the release of the sheet like preparation by the release mechanism.
Type:
Grant
Filed:
December 22, 2015
Date of Patent:
August 18, 2020
Assignee:
Universität Greifswald
Inventors:
Malte Bogdahn, Kirsten Kirsch, Michael Grimm, Mirko Koziolek, Werner Weitschies
Abstract: The invention relates to the discovery that HNA-3a and HNA-3b are antigens within a polypeptide sequence that is highly similar to the CTL2 amino acid sequence. This invention provides methods and kits for screening for HNA-3a and HNA-3b specific antibodies, HNA-3a and HNA-3b polypeptides and HNA-3a and HNA-3b nucleic acids in a sample of a biological tissue intended for transplantation.
Type:
Grant
Filed:
April 3, 2015
Date of Patent:
May 8, 2018
Assignees:
ERNST-MORITZ-ARNDT-UNIVERSITÄT GREIFSWALD, DRK BLUTSPENDEDIENST WEST GMBH
Inventors:
Andreas Greinacher, Jan Wesche, Juergen Bux, Angelika Reil
Abstract: The present invention relates to imidazolium salts, particularly imidazolium salts of the general formula I as well as the respective carbene metal complexes and their utilization as bioanalytical tags for biomolecules.
Abstract: The invention relates to the discovery that HNA-3a and HNA-3b are antigens within a polypeptide sequence that is highly similar to the CTL2 amino acid sequence. This invention provides methods and kits for screening for HNA-3a and HNA-3b specific antibodies, HNA-3a and HNA-3b polypeptides and HNA-3a and HNA-3b nucleic acids in a sample of a biological tissue intended for transplantation.
Type:
Grant
Filed:
March 18, 2013
Date of Patent:
April 7, 2015
Assignees:
Ernst-Moritz-Arndt-Universität Greifswald, DRK Blutspendedienst West GmbH
Inventors:
Andreas Greinacher, Jan Wesche, Juergen Bux, Angelika Reil
Abstract: The invention relates to the discovery that HNA-3a and HNA-3b are antigens within a polypeptide sequence that is highly similar to the CTL2 amino acid sequence.
Type:
Application
Filed:
March 18, 2013
Publication date:
July 25, 2013
Applicants:
DRK BLUTSPENDEDIENST WEST GMBH, ERNST-MORITZ-ARNDT-UNIVERSITAT GREIFSWALD
Inventors:
Andreas Greinacher, Jan Wesche, Juergen Bux, Angelika Reil
Abstract: The present invention relates to imidazolium salts, particularly imidazolium salts of the general formula I as well as the respective carbene metal complexes and their utilisation as bioanalytical tags for biomolecules.
Abstract: The invention relates to the discovery that HNA-3a and HNA-3b are antigens within a polypeptide sequence that is highly similar to the CTL2 amino acid sequence. This invention provides methods and kits for screening for HNA-3a and HNA-3b specific antibodies, HNA-3a and HNA-3b polypeptides and HNA-3a and HNA-3b nucleic acids in a sample of a biological tissue intended for transplantation.
Type:
Grant
Filed:
November 29, 2011
Date of Patent:
May 7, 2013
Assignees:
Ernst-Moritz-Arndt-Universität Greifswald, DRK Blutspendedienst West GmbH
Inventors:
Andreas Greinacher, Jan Wesche, Juergen Bux, Angelika Reil
Abstract: The invention relates to the discovery that HNA-3a and HNA-3b are antigens within a polypeptide sequence that is highly similar to the CTL2 amino acid sequence. This invention provides methods and kits for screening for HNA-3a and HNA-3b specific antibodies, HNA-3a and HNA-3b polypeptides and HNA-3a and HNA-3b nucleic acids in a sample of a biological tissue intended for transplantation.
Type:
Application
Filed:
November 29, 2011
Publication date:
March 22, 2012
Applicants:
DRK BLUTSPENDIENST WEST GMBH, ERNST-MORITZ-ARNDT-UNIVERSITÄT GREIFSWALD
Inventors:
ANDREAS GREINACHER, JAN WESCHE, JUERGEN BUX, ANGELIKA REIL
Abstract: The invention relates to the discovery that HNA-3a and HNA-3b are antigens within a polypeptide sequence that is highly similar to the CTL2 amino acid sequence. This invention provides methods and kits for screening for HNA-3a and HNA-3b specific antibodies, HNA-3a and HNA-3b polypeptides and HNA-3a and HNA-3b nucleic acids in a sample of a biological tissue intended for transplantation.
Type:
Grant
Filed:
September 3, 2009
Date of Patent:
December 27, 2011
Assignees:
Ernst-Moritz-Arndt-Universität Greifswald, DRK Blutspendedienst West GmbH
Inventors:
Andreas Greinacher, Jan Wesche, Juergen Bux, Angelika Reil
Abstract: The invention relates to the discovery that HNA-3a and HNA-3b are antigens within a polypeptide sequence that is highly similar to the CTL2 amino acid sequence.
Type:
Application
Filed:
September 3, 2009
Publication date:
March 4, 2010
Applicants:
ERNST-MORITZ-ARNDT-UNIVERSITAT GREIFSWALD, DRK BLUTSPENDEDIENST WEST GMBH
Inventors:
Andreas Greinacher, Jan Wesche, Juergen Bux, Angelika Reil
Abstract: An implant for implantation in a human or animal body having a structure comprising a) an implant base body; b) a primer layer which is partially or completely applied to the surface of the implant; c) an active ingredient layer consisting of one, two, three or more active ingredients applied entirely or partially to the surface of the primer layer; and d) a diffusion-controlling layer which is applied partially or entirely to the active ingredient layer, and optionally to the primer layer, wherein diffusion of the active ingredients of the active ingredient layer is controlled. Also disclosed is a manufacturing method for an implant.
Type:
Application
Filed:
December 10, 2008
Publication date:
June 11, 2009
Applicants:
BIOTRONIK VI PATENT AG, UNIVERSITAT ROSTOCK, UNIVERSITAT GREIFSWALD
Inventors:
Klaus-Peter Schmitz, Detlef Behrend, Katrin Sternberg, Niels Grabow, Claus Harder, Bjoern Klocke, Heyo K. Kroemer, Werner Weitschies
Abstract: The invention relates to the use of inhibitors of the multidrug resistance protein 4 (MRP4) in thrombocytes for the treatment and/or prophylaxis of cardiovascular diseases.
Abstract: The present invention relates to the influence of the activity and/or the expression of the multifunctional transcription factor Yin Yang 1 (YY1), and of variants thereof, for the treatment of many different illnesses. The invention especially relates to a mutated nucleic acid sequence which encodes a variant of the human YY1 and has a protective action against diabetes, according to the present invention.